Skip to content

Single-Cell Discovery Grant in Oncology and Immunology

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunology.

Immunological diseases and Cancer are complex disorders and pose an enormous clinical burden due to diagnosis, stratification, and treatment challenges. Single-cell technologies are powerful in analysing the cellular landscape within complex diseases and are increasingly popular as a tool in identifying rare cells underlying the etiology of disease onset and progression in these areas. 

Scailyte is a recognized leader in combining single-cell analysis with artificial intelligence (AI) based data analytics. Our best-in-class algorithm associates patterns in single-cell data with disease status and further integrates multiple clinical parameters for a sensitive and impactful discovery.

We offer a co-finance partnership sharing 50% of costs (up to 100K Euro) for single-cell data acquisition including scRNA sequencing and CyTOF analysis, and subsequent artificial intelligence (AI)-based high-end bioinformatics services for translational oncology and immunology projects. The expected outcome of these grants should be addressing unmet medical needs and targets the discovery of clinically relevant biosignatures from single-cell data for diagnostic and prognostic pharmaceutical use. A maximum of three projects will be selected for this award through a formal selection process and notified within one month of the deadline.

Application:

Link to the brief application form: Click Here 

Deadline: 30th September 2021

Recent News

VACANCY: Regulatory Affairs / Quality Management Specialist

We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu

Read more

Recent News

Scailyte Webinar - Why single-cell technologies are vital for Endometriosis research

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th

Read more

Recent News

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Read more

Recent News

Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Recent News

Scailyte Quarterly Update, June 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich

Read more

Recent News

Scailyte Quarterly Update, April 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

01 /04

VACANCY: Regulatory Affairs / Quality Management Specialist

We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu

Read more

Scailyte Webinar - Why single-cell technologies are vital for Endometriosis research

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th

Read more

Recent News

02 /04

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Read more

Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Recent News

03 /04

Scailyte Quarterly Update, June 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich

Read more

Recent News